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Abstract
Background: Yusho an intoxication caused by oral dioxins and polychlorinated biphenyls occurred in 1968.
Patients suffered from various systemic symptoms, including general fatigue, nausea, muscular and articular pain,
acneform eruptions, black comedones, cutaneous and oral pigmentation, and increased eye discharge. The major
causative factor was the contamination of rice oil with 2,3,4,7,8-penta-chlorodibenzofuran (PeCDF). Recent
technical advances have allowed us to measure blood levels of PeCDF. However, there is little information on
which symptoms and laboratory data are directly associated with PeCDF levels.
Methods: Yusho patients underwent annual medical check-ups from 2001 to 2003. Blood PeCDF levels were
correlated with the presence or absence of symptoms in medical, hematological, dermatological, dental and
ophthalmological examinations. This study analyzed all combinations by using the association analysis. This is the
most suitable method to evaluate all combinations of the data comprehensively. This method was used to
determine the rate of patients with high PeCDF level in the population with each symptom, and to extract
combinations of three symptoms which were strongly associated with high PeCDF level.
Results and Conclusion: The rate of the patients with high PeCDF level was high in populations with high uric
acid, black comedones (face), second highest quartile of age, or high urea nitrogen. The combination of three
symptoms associated with the highest rate of patients with high PeCDF level was "high uric acid, female sexuality,
and history of acneform eruptions", followed by "history of Yusho in and after 1968, high cholesterol level, and
subjective symptoms." This analysis newly suggested that PeCDF concentration may be associated with history of
dermatological symptoms, high uric acid, and elevated erythrocyte sedimentation rate.
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Background
A mass food poisoning involving at least 1900 individuals
occurred in northern Kyushu of Japan in 1968. The poi-
soning was called Yusho (oil disease) because it was
caused by ingestion of rice bran oil which was contami-
nated with Kanechlor-400, a commercial, Japanese brand
of polychlorinated biphenyls (PCBs). It was later found
that the rice bran oil had been contaminated not only
with PCBs, but also with various dioxins. Among these
PCB-related compounds, 2,3,4,7,8-penta-chlorodibenzo-
furan (PeCDF), a highly toxic dioxin, was considered to be
the major causative factor [1-5]. The World Health Organ-
ization re-evaluated the toxic equivalency factors (TEFs)
for seven polycholorinated dibenzo-p-dioxins, 10 poly-
chlorinated dibenzofurans and 12 coplanar PCBs. TEFs
for 2,3,4,7,8-PeCDF and 2,3,3',4,4',5-hexachlorobiphenyl
(PCB 156) are 0.3 and 0.00003, respectively, compared to
1.0 for the most toxic dioxin, 2,3,7,8-tetracholorod-
ibenzo-p-dioxin [6].
Non-specific subjective symptoms such as general fatigue,
weight loss and anorexia were observed in most patients
[7]. In addition to these general symptoms, various char-
acteristic objective symptoms gradually appeared in
patients, including dermatological symptoms (come-
dones, acneform eruptions, black spots in hair pores, and
dark-brown pigmentation of skin and nails), ophthalmo-
logical symptoms (increased cheesy secretions from mei-
bomian glands, conjunctival pigmentation, cysts of
meibomian glands and edema of the eyelids), and oral
symptoms (gingival pigmentation). A considerable
number of patients also suffered from headaches, par-
esthesia of the extremities, abdominal pain, cough and
sputum, altered menstruation, and small-for-date babies.
Jaundice and palpable spleen were not observed [1,8-10].
At the time of the outbreak, blood levels of PeCDF were
estimated to be as high as > 60,000 pg/g lipids [11]. How-
ever, due to technical limitations, blood levels of PeCDF
have not been routinely measured until recently. It was
started to examine the blood levels of PeCDF in 2001 and
found that PeCDF levels were still significantly high in
Yusho patients compared with normal controls. Accord-
ingly, we amended the diagnostic criteria for Yusho in
2004 by adding an item of "abnormal blood level of
PeCDF" (Table 1). A PeCDF blood level of ≥50 pg/g lipids
was considered abnormally high compared to that in nor-
mal controls. More than 35 years have elapsed since the
outbreak of Yusho and the specific symptoms in Yusho
patients have gradually disappeared. However, no studies
have addressed the direct relationship/association
between PeCDF blood levels and clinical/laboratory
symptoms.
With recent technical advances in the measurement of
dioxins such as PeCDF, it has become possible to measure
blood PeCDF levels during routine annual medical check-
ups in Yusho patients. Since 2001, measurement of blood
PeCDF level has been carried out not only in Yusho
patients (determined patients), but also in persons who
had not yet been determined as having Yusho (undeter-
mined cases) [12,13]. Therefore, it is now possible to
determine which symptoms and laboratory abnormalities
are actually related to PeCDF blood levels. Although rou-
tine logistic regression analyses and analyses of variance
have been conducted many times, the results demon-
strated that the associations between PeCDF and clinical
symptoms did not completely correspond with the
impressions of medical practitioners who were actually
engaged in the diagnosis. When combinations of symp-
toms characteristic for PeCDF were extracted as a trial, it
was pointed out that combinations corresponding with
the impressions of medical practitioners became availa-
ble. The procedure that allowed the most efficient extrac-
tion of combinations of characteristic symptoms was
selected to conduct more detailed analyses. For this high-
capacity data analysis, we took advantage of recent data
mining techniques.
Methods
Symptoms and laboratory examinations performed in 
Yusho patients during annual medical check-ups
Following the outbreak of Yusho, medical check-ups for
more than 1900 Yusho-determined patients were con-
ducted at follow-up in several prefectures for > 30 years.
Yusho medical check-ups consisted of a total of 241 items,
including 55 interview and physical items, 21 dermato-
logical, five ophthalmological, 108 dental, and 52 labora-
tory examinations [1,13,14]. Medical data from 477
patients who underwent Yusho medical check-ups from
2001 to 2003 were selected for this study. Subjective
symptoms were general fatigue, headache, cough, spu-
tum, abdominal pain, diarrhea, constipation, numbness,
arthralgia, and altered menstruation. Physical examina-
tions included body height, body weight, pulse rate,
blood pressure, nutrition, heart sounds, respiratory
sounds, hepatomegaly, splenomegaly, edema, lymphade-
nopathy, as well as tendon reflexes, sensory examination,
chest radiography, electrocardiography, and abdominal
ultrasonography. Dermatological symptoms evaluated
included black comedones, acneform eruptions, scar for-
mation, pigmentation of skin and nails, and nail deform-
ity. Ophthalmological symptoms evaluated included
abnormal eye discharge, edema of the eyelid, conjunctival
pigmentation, meibomian gland cysts, and cheesy secre-
tions from meibomian glands. Dental and oral manifesta-
tions evaluated included gingivitis, marginal
periodontitis, retarded eruption of permanent teeth, tooth
pigmentation, odontogenesis imperfecta, abnormal
occlusion, and pigmentation of gingival mucosa, buccal
mucosa, palate and lips. Laboratory examinationsBMC Research Notes 2009, 2:27 http://www.biomedcentral.com/1756-0500/2/27
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included blood levels of PeCDFs, complete blood cell
counts, erythrocyte sedimentation rate, blood chemistry,
blood hepatitis B antigen, and alfa-fetoprotein. Sex, quar-
tile age, and information on determined/undetermined
status were also used in the analyses.
Methods of data analysis
This study analyzed all combinations by using association
analysis [15]. This is the most suitable method to evaluate
all combinations of the data comprehensively. This
method was used to determine the proportion of high
level PeCDF in the population with each symptom, and to
extract combinations of three symptoms which were
strongly associated with high PeCDF level. Logistic-regres-
sion analysis can be used to evaluate the links between
factors and a disease. However, this is a method to evalu-
ate the linkage with only one such factor. Therefore, this is
not suitable, for example, to find three primary symp-
toms. In contrast, association analysis is the most suitable
method to evaluate combinations of the data comprehen-
sively. Association analysis is also known as the term
"market basket analysis," which analyzes a tendency that
some items are bought with others.
Table 1: Diagnostic criteria for Yusho (as presently supplemented)
The diagnostic criteria for Yusho were revised on October 26, 1972; supplemented on June 14, 1976; and an item related to blood polychlorinated 
quarterphenyl (PCQ) level was added on June 16, 1981. The study group of Yusho started to measure blood levels of dioxins in annual medical 
check-ups from 2001. It was considered appropriate to add an item corresponding to the blood 2,3,4,7,8-penta-chlorodibenzofurans (PeCDF) level; 
therefore the criteria were supplemented and further revised on September 29, 2004.
Conditions of onset
1) Ingestion of Kanemi rice bran oil contaminated with PCBs,
2) Vertical PCB transmission from mothers with Yusho to infants in some cases,
3) Familial occurrence seen in many cases
Important manifestations
1. Acneform eruptions
Black comedones seen on the face, buttocks and other intertriginous sites; comedones with inflammatory manifestations; and subcutaneous cysts 
with atheroma-like contents that tended to suppurate.;
2. Pigmentation
Pigmentation of the face, palpebral conjunctivae, gingivae, and nails etc. (including so-called 'black babies');
3. Hypersecretion of the meibomian glands;
4. Unusual composition and concentration of PCBs in the blood;
5. Abnormal level of blood PCQ
1) ≥ 0.1 ppb: an abnormally high concentration,
2) 0.03 to 0.09 ppb: the boundary between high and normal concentrations,
3) ≤ 0.02 ppb (detection limit): normal concentration;
6. Abnormal level of blood PeCDF
1) ≥ 50 pg/g lipids: an abnormally high concentration,
2) 30 to 50 pg/g lipids: a relatively high concentration,
3) < 30 pg/g lipids: normal concentration]
Standard symptoms and findings
1. Subjective symptoms
1) General fatigue,
2) Headaches, dull headaches,
3) Paresthesia of the extremities (abnormal sensation),
4) Increased eye discharge,
5) Cough and sputum,
6) Constant abdominal pain,
7) Altered menstruation
2. Objective findings
1) Manifestation of bronchitis,
2) Deformation of nails,
3) Bursitis,
4) Increased neutral fat in the serum,
5) Increased serum γ-glutamyl transpeptidase (γ-GTP),
6) Decrease in serum bilirubin,
7) Small-for-date baby,
8) Growth retardation and dental abnormality (retarded eruption of permanent teeth)BMC Research Notes 2009, 2:27 http://www.biomedcentral.com/1756-0500/2/27
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We used the association analysis as a method to find out
the three symptoms [16]. This study determined the pro-
portion of the patients with high PeCDF level in the pop-
ulation with each symptom, and extracted combinations
of three symptoms which were strongly associated with
high PeCDF level.
Results
Rate of the patients with high PeCDF level in the 
population with each symptom
Table 2 shows rate of the patients with high PeCDF level
in the population with each symptom. The rate was high-
est in the population with black comedones (trunk), fol-
lowed by the population with high uric acid. However,
the black comedone (trunk) was not statistically signifi-
cant, because the rate of patients with the symptom was
too low. In contrast, high uric acid was statistically signif-
icant, because the rate of patients with the symptom was
adequate. High uric acid was followed by black come-
dones (face), third quartile of age, and high urea nitrogen.
Rate of patients with high PeCDF level in the population 
with each three-symptom combination
Table 3 shows 10 populations with three-symptom com-
binations having the highest rate of patients with high
PeCDF level. In the population with high uric acid, female
sexuality, and history of acneform eruptions, 88.89% of
the patients had high PeCDF level. This is the highest rate
among all combinations of three symptoms. The second
highest rate was seen in the combination of history of
Yusho in and after 1968, high cholesterol level, and pres-
ence of subjective symptoms. The 10 combinations listed
in the table 3 were all statistically significant.
Discussion
The mean blood level of PeCDF in patients with Yusho
was 11.6–16.8 times higher than the mean levels in nor-
mal controls. It is known that dioxins and PCBs remain in
tissues for a long time. It is of note that even 40 years after
the outbreak, high concentrations of dioxins remained in
the blood of patients with Yusho.
Many studies have been conducted on Yusho, however,
few have reported analysis on symptoms and PeCDF lev-
els. There are two main reasons for this: (i) PeCDF meas-
urements include large errors; and (ii) no distinction can
be made between specific symptoms and changes due to
aging, since more than 40 years have passed since the
occurrence. Therefore, routine logistic regression analysis
cannot clarify the relationship between the symptoms and
PeCDF levels.
The level of PeCDF was high in patients with black come-
dones (trunk). However, since there were few patients
with the symptom, the association was not judged as sta-
tistically significant. The symptom judged as statistically
significant was high uric acid. Although diagnostic criteria
for Yusho do not include the uric acid, the uric acid level
was high in elderly Yusho patients. It might be a symptom
that has been manifested recently.
A population with three-symptom combination showing
high rate of patients with high PeCDF level tends to have
(1) female sexuality, (2) dermatological symptoms incor-
porated in the diagnostic criteria such as histories of
"acneform eruptions" and "pigmentation," and (3) symp-
toms such as "high uric acid" and "elevated erythrocyte
sedimentation rate." Although "high uric acid" is a symp-
tom strongly associated with males, it was seen linked
with females. The symptom may be enhanced due to the
aging of the patients.
Principal component analyses have revealed that PeCDF
level is strongly associated with PCB and polychlorinated
quarterphenyl (PCQ) levels, and also associated with
blood glucose, arthralgia, total cholesterol, urine sugar, 2-
hour erythrocyte sedimentation rate, thymol, and sodium
as well as conventionally known dermatological symp-
Table 2: Rate of patients with high PeCDF level in population with each symptom
Rank Symptoms Rate of patients with the symptom Rate of patients with high PeCDF 
(> 50 pg/g lipids)
1 Black comedones (trunk) <+ or severer> 0.0671 0.6563
2 uric acid (high) 0.1761 0.6310*
3 Black comedones (face) <+ or severer> 0.0860 0.6098
4 Third quartile age 0.2348 0.6071*
5 urea nitrogen (high) 0.1111 0.6038
6 red blood cell count (low) 0.1342 0.5938
7 History of pigmentation <present> 0.3669 0.5886*
8 Classification of testee <qualified> 0.7526 0.5794*
9 Subjective symptoms, etc. <present> 0.1488 0.5775
10 Second quartile age 0.2788 0.5714
* Statistically significant symptomsBMC Research Notes 2009, 2:27 http://www.biomedcentral.com/1756-0500/2/27
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toms such as acneform eruptions and black comedones,
and total bilirubin.
Nearly 40 years have elapsed since the outbreak of Yusho,
and the patients have become old. Differentiating Yusho
symptoms from alterations due to aging is difficult, but
the analysis suggested that PeCDF level may be associated
with the history of dermatological symptoms, high uric
acid, and elevated erythrocyte sedimentation rate.
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